Abstract: A skincare composition and a method for ameliorating the effects of aging. The skincare composition comprises an enhanced extract obtained from plant seeds germinated in an environment that includes an effective amount of sucrose and enriched levels of oxygen, and a cosmetically acceptable carrier.

Abstract: Provided are formulations that interact with the skin microbiome of a human patient such that when applied topically in therapeutically effective amounts at prescribed intervals, the formulations cause an increase in skin firmness, density, smoothness, elasticity and thickness resulting in a skin appearance that reflects overall skin health. In exemplary embodiments formulations include, without limitation, the following active components acting in concert with each other: a prebiotic component, a peptide component, a matrix metalloproteinases (MMPs) inhibitor component; and an antioxidant component; all present in a carrier base. The exemplary embodiments may be in the form of a cream, a lotion, a serum, or a hydrogel that facilitates delivery of these active components into the skin.

Abstract: Provided are formulations that interact with the skin microbiome of a human patient such that when applied topically in therapeutically effective amounts at prescribed intervals, the formulations cause an increase in skin firmness, density, smoothness, elasticity and thickness resulting in a skin appearance that reflects overall skin health. In exemplary embodiments formulations include, without limitation, the following active components acting in concert with each other: a prebiotic component, a peptide component, a matrix metalloproteinases (MMPs) inhibitor component; and an antioxidant component; all present in a carrier base. The exemplary embodiments may be in the form of a cream, a lotion, a serum, or a hydrogel that facilitates delivery of these active components into the skin.

Abstract: A skincare formulation for reducing facial expression lines via multi-modal reduction of ACh concentration and activity. The formulation includes a carrier base, an inhibitory neurotransmitter and a plurality of neuromodulating peptides configured to inhibit ACh concentration and activity at the epidermis as well as at the neuro-muscular junction The inhibitory neurotransmitter is configured to reduce neuronal excitability.

Abstract: Provided are formulations that interact with the skin microbiome of a human patient such that when applied topically in therapeutically effective amounts at prescribed intervals, the formulations cause an increase in skin firmness, density, smoothness, elasticity and thickness resulting in a skin appearance that reflects overall skin health. In exemplary embodiments formulations include, without limitation, the following active components acting in concert with each other: a prebiotic component, a peptide component, a matrix metalloproteinases (MMPs) inhibitor component; and an antioxidant component; all present in a carrier base. The exemplary embodiments may be in the form of a cream, a lotion, a serum, or a hydrogel that facilitates delivery of these active components into the skin.

Abstract: There are presented topical formulations and methods of applying these formulations in therapeutically effective amounts directly to areas of the human skin to remediate and to counter effects that are commonly regarded as aging. The formulations address the effects on the skin of UV light, High Energy Visible (HEV) light, blue light, and Urban Dust as well as remediating fine lines and age-related localized melanin concentrations (“age spots”), improving the uniformity of skin tone (reduction in skin redness) and enhancing the brightness of the skin to provide a more youthful appearance. Skin treated with the formulations also exhibit a reduction in the depth and prominence of wrinkles, a marked reduction in harmful reactive oxygen species in the treated skin, and a reduction in lipid peroxidation caused by Urban Dust.

Abstract: The present invention relates to a method of preparing enantiomers and diastereomers of a 2′,3′-dideoxy-5-fluoro-3′thiocytadine (FTC) or a derivative thereof as represented by the structural formula (I), wherein R is H, a substituted or unsubstituted organic acid radical, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroarakyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstitued cycloalkylalkyl group, a substituted or unsubstituted heterocycloalkylalkyl group, a sugar or a protecting group.

Abstract: The present invention relates to a method of preparing enantiomers and diastereomers of a 2′,3′-dideoxy-5-fluoro-3′thiocytadine (FTC) or a derivative thereof as represented by the following structural formula: In Structural Formula I, R is H, a substituted or unsubstituted organic acid radical, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaralkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted cycloalkylalkyl, a substituted or unsubstituted heterocycloalkylalkyl, a sugar or a protecting group.

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: 1

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: In Structural Formula I, R is an amine protecting group, and R1 is an amino acid side-chain, a protected amino acid side-chain, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl group. The method involves contacting a 1-nitro-3-substituted-3-amino-2-propanone with a reducing agent to form a mixture of 1-nitro-3-substituted-3-amino-2-propanol diastereomers. The 1-nitro-3-substituted-3-amino-2-propanol diastereomers are then separated by simulated moving bed chromatography to obtain one or more 1-nitro-3-substituted-3-amino-2-propanol diastereomer.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.The method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.This method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.This method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.The method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds.

Abstract: The present invention relates to a method of forming a 1,3-diamino-3-substituted-2-propanol chemical intermediate from which various chemicals, such as selected protease-inhibitors and other drugs, as well as polymers, can be synthesized.This method includes contacting a nitromethyl amino acid compound with at least one reducing agent to form the 1,3-diamino-3-substituted-2-propanol chemical intermediate.

Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).